Orthofix: Q1 Earnings Snapshot
On a per-share basis, the Lewisville, Texas-based company said it had a loss of $1.35. Losses, adjusted for non-recurring costs and stock option expense, were 8 cents per share.
The medical device maker posted revenue of $193.6 million in the period.
Orthofix expects full-year revenue in the range of $808 million to $816 million.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Miami Herald
38 minutes ago
- Miami Herald
Stocks and Markets Podcast: Prairie Operating CEO on energy business
Ed Kovalik wants you to know the importance of petroleum. "I always remind people that everything in their daily life is made in some way, shape, or form with a petroleum-based product," he said. "The computers that we're using right now to talk to one another, with the makeup that our wives wear, the surfboard my kids use at the beach," Kobalik added. "They're fossil fuels and everything, fossil fuels, everything. I think the only thing I've ever seen that's as prolific is corn," Don't miss the move: Subscribe to TheStreet's free daily newsletter Kovalik, chairman and CEO of Houston-based Prairie Operating Co. (ticker: PROP) shared his experiences with Chris Versace, TheStreet Pro portfolio's lead manager, during the July 16 edition of TheStreet Stocks & Markets Podcast. "We're energy-dense form of energy," he said. "The only competitive form of energy is nuclear. And nuclear is going to take decades to work itself out of the regulatory quagmire that it's in and get built going to see demand for fossil fuels increase every year." Fossil fuels play an important role in meeting the ever-growing demands of AI data centers, he said. Goldman Sachs Research forecast in February that global power demand from data centers will increase 50% by 2027 and by as much as 165% by the end of the decade compared with 2023. More Economic Analysis: Federal Reserve prepares strong message on long-term interest ratesMassive city workers union approves strikeAnalyst makes bold call on stocks, bonds, and gold "Low-energy-dense forms of generation like solar and wind are not going to take over the industry," Kovalik said. Kovalik, who came out of the investment banking world, said he fell in love with the industry during the first generation of shale companies that emerged in the early went on to work in private equity and merchant banking, investing in mostly upstream exploration and production across all the basins in the US. "We started Prairie two years ago, really with a very focused mission to create a pure play under levered, high growth, DJ basin focused smidcap company," he said, referring to the Denver-Julesburg Basin centered in eastern Colorado. "And so that was really in response to what we've seen over the last decade, which has been a massive amount of consolidation in our industry." Today there are far fewer public oil companies, he said, and far fewer small-cap companies, in particular. "There are no growth-oriented small-cap companies," Kovalik said. "And so we really wanted to create an investment alternative that looked like that." "So, it's fair to say that you've seen the trials, the tribulations, the rewards, throughout economic cycles and what commodity prices have done," Versace said. "So, you're well aware of the bigger opportunities and mindful of the risks." "Yeah, 100%," Kovalik said. "In that period of time shale has been through an entire evolution from the first days of drilling to today. From a pure operational technological perspective, a lot of innovation has happened in the industry, where we're able to drill much better wells than we did 25 years ago." M&A is a pillar of the company's strategy, he said, noting that Prairie Operating recently acquired the assets of Edge Energy for $12.5 million. Related: Stocks and Markets Podcast: Why Now Is the Time to Buy High-Yielding Small-Cap Stocks "When we purchased the Bayswater assets, for example, we hedged 85% of that production on a three-year roll-forward basis," he said. (The $603 million deal closed in February.) "I think we locked in our oil-price hedges at $68 (per barrel) and change and our gas hedges above $4 (per 1,000 cubic feet), and so we're big believers in taking that risk off as we drill wells, which we're doing every day." "We'll continue to hedge as we bring those new wells [into] production," Kovalik said. "And so that's the biggest risk." "We've talked a little bit about the oil market, the opportunities with Prairie," Versace said. "But, for someone who's new to the story, Ed, what are the one or two risks that you and the rest of the management team continue to focus in on, or [that folks should be] mindful of?" "The] big elephant in the room is commodity price risk," Kovalik said. "And you can't be an oil company without assuming that risk. We hedge for that. So we're certainly not believers in the idea that people ought to buy Prairie stock as a way to expose themselves to oil prices." "You can do that yourself without we do is we try to eliminate that risk to the best of our ability." Related: Fund-management veteran skips emotion in investment strategy The Arena Media Brands, LLC THESTREET is a registered trademark of TheStreet, Inc.
Miami Herald
an hour ago
- Miami Herald
Tech firm CEO resigns amid Coldplay concert kiss cam controversy
Software developer Astronomer says former Chief Executive Officer Andy Byron resigned amid controversy following his attendance at a recent Coldplay concert. New York-based Astronomer confirmed Byron's resignation on Saturday and said co-founder and Chief Product Officer Pete DeJoy is its interim chief executive officer while its board of directors seeks a permanent replacement for Byron. 'Astronomer is committed to the values and culture that have guided us since our founding,' Astronomer officials said Saturday in a post on X. 'Our leaders are expected to set the standard in both conduct and accountability, and recently, that standard was not met.' Byron is married but was caught attending a Coldplay concert with another woman on Wednesday night at Gillette Stadium in Foxborough, Mass. The stadium's 'kiss cam' zeroed in on Byron with his arms wrapped around a woman standing in front of him during the concert, NBC News reported. When they realized they were on the kiss cam, Byron ducked out of the camera shot, while the unidentified woman covered her face. Coldplay's lead singer Chris Martin noticed the pair's reaction during the concert and opined: 'Either they're having an affair or they're just very shy.' The video of the moment went viral, and social media sleuths identified the man as Byron. Astronomer placed him on leave on Friday before accepting his resignation a day later, according to NBC News. The tech firm is a relatively small company with fewer than 500 employees and noted the viral incident's impact on its operations. 'While awareness of our company may have changed overnight, our product and our work for our customers have not,' Astronomer said in its X post. 'We're continuing to do what we do best: helping our customers with their toughest data and AI problems.' Copyright 2025 UPI News Corporation. All Rights Reserved.
Yahoo
2 hours ago
- Yahoo
H.C. Wainwright Reiterates a Buy Rating on Lexicon Pharmaceuticals (LXRX)
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) is one of the . H.C. Wainwright analyst Joseph Pantginis maintained a Buy rating on Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) on June 24, keeping the associated price target at $4.00. A laboratory researcher in a white coat, closely examining a microscope. The analyst reasoned that Lexicon Pharmaceuticals, Inc.'s (NASDAQ:LXRX) sotagliflozin has a promising clinical profile for Type 1 Diabetes (T1D) patients and has exhibited a notable drop in hypoglycemic events. Since this is a significant concern in T1D management, it brings a positive light to the company's operations. Pantginis further stated that Phase 3 inTandem1 and inTandem2 clinical trial results showed a significant reduction in hypoglycemia rates compared to a placebo when sotagliflozin was used alongside optimized insulin therapy. This effect was the same across different subgroups defined by kidney function, showing sotagliflozin's broad applicability. Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) discovers, develops, and commercializes pharmaceutical products. The company's drug candidates include Sotagliflozin for treating heart failure and type 1 diabetes, and LX9211 as a treatment for neuropathic pain. While we acknowledge the potential of LXRX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
